295 results on '"*PORTAL vein surgery"'
Search Results
2. Long-term survival of ALPPS procedure for hepatocellular carcinoma with tumor thrombus in the right branch of portal vein: A case report.
- Author
-
Wang QQ, Quan XL, Zhang Y, and Shu GM
- Subjects
- Humans, Male, Time Factors, Treatment Outcome, Middle Aged, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular complications, Liver Neoplasms surgery, Liver Neoplasms complications, Liver Neoplasms pathology, Portal Vein surgery, Hepatectomy methods
- Abstract
Competing Interests: Declaration of competing interest The authors declare that there are no potential financial or nonfinancial conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
3. Comprehensive review of hepatocellular carcinoma with portal vein tumor thrombus: State of art and future perspectives.
- Author
-
Gavriilidis P, Pawlik TM, and Azoulay D
- Subjects
- Humans, Hepatectomy, Portal Vein pathology, Portal Vein surgery, Treatment Outcome, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular therapy, Carcinoma, Hepatocellular mortality, Liver Neoplasms pathology, Liver Neoplasms therapy, Liver Neoplasms surgery, Venous Thrombosis etiology, Venous Thrombosis surgery, Venous Thrombosis pathology
- Abstract
Background: Despite advances in the diagnosis of patients with hepatocellular carcinoma (HCC), 70%-80% of patients are diagnosed with advanced stage disease. Portal vein tumor thrombus (PVTT) is among the most ominous signs of advanced stage disease and has been associated with poor survival if untreated., Data Sources: A systematic search of MEDLINE (PubMed), Embase, Cochrane Library and Database for Systematic Reviews (CDSR), Google Scholar, and National Institute for Health and Clinical Excellence (NICE) databases until December 2022 was conducted using free text and MeSH terms: hepatocellular carcinoma, portal vein tumor thrombus, portal vein thrombosis, vascular invasion, liver and/or hepatic resection, liver transplantation, and systematic review., Results: Centers of surgical excellence have reported promising results related to the individualized surgical management of portal thrombus versus arterial chemoembolization or systemic chemotherapy. Critical elements to the individualized surgical management of HCC and portal thrombus include precise classification of the portal vein tumor thrombus, accurate identification of the subgroups of patients who may benefit from resection, as well as meticulous surgical technique. This review addressed five specific areas: (a) formation of PVTT; (b) classifications of PVTT; (c) controversies related to clinical guidelines; (d) surgical treatments versus non-surgical approaches; and (e) characterization of surgical techniques correlated with classifications of PVTT., Conclusions: Current evidence from Chinese and Japanese high-volume centers demonstrated that patients with HCC and associated PVTT can be managed with surgical resection with acceptable results., (Copyright © 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. The speed of liver regeneration in ALPPS may be influenced by hypoxia at high altitudes: A case report.
- Author
-
Chen B, Da W, Ba-Sang DZ, and Xu HF
- Subjects
- Humans, Male, Portal Vein surgery, Adult, Time Factors, Liver surgery, Liver Regeneration physiology, Hepatectomy methods, Altitude, Hypoxia etiology
- Published
- 2024
- Full Text
- View/download PDF
5. Efficacy and perioperative safety of different future liver remnant modulation techniques: a systematic review and network meta-analysis.
- Author
-
Bozkurt E, Sijberden JP, Kasai M, and Abu Hilal M
- Subjects
- Humans, Treatment Outcome, Ligation, Risk Factors, Postoperative Complications etiology, Postoperative Complications prevention & control, Liver Neoplasms surgery, Female, Male, Liver Regeneration, Middle Aged, Hepatectomy methods, Hepatectomy adverse effects, Portal Vein surgery, Embolization, Therapeutic adverse effects, Network Meta-Analysis
- Abstract
Background: In daily clinical practice, different future liver remnant (FLR) modulation techniques are increasingly used to allow a liver resection in patients with insufficient FLR volume. This systematic review and network meta-analysis aims to compare the efficacy and perioperative safety of portal vein ligation (PVL), portal vein embolization (PVE), liver venous deprivation (LVD) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)., Methods: A literature search for studies comparing liver resections following different FLR modulation techniques was performed in MEDLINE, Embase and Cochrane Central, and pairwise and network meta-analyses were conducted., Results: Overall, 23 studies comprising 1557 patients were included. LVD achieved the greatest increase in FLR (17.32 %, 95% CI 2.49-32.15), while ALPPS was most effective in preventing dropout before the completion hepatectomy (OR 0.29, 95% CI 0.15-0.55). PVL tended to be associated with a longer time to completion hepatectomy (MD 5.78 days, 95% CI -0.67-12.23). Liver failure occurred less frequently after LVD, compared to PVE (OR 0.35, 95% CI 0.14-0.87) and ALPPS (OR 0.28, 95% CI 0.09-0.85)., Discussion: ALPPS and LVD seem superior to PVE and PVL in terms of achieved FLR increase and subsequent treatment completion. LVD was associated with lower rates of post hepatectomy liver failure, compared to both PVE and ALPPS. A summary of the protocol has been prospectively registered in the PROSPERO database (CRD42022321474)., (Copyright © 2024 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Portal vein embolization combined with ex vivo liver resection and autotransplantation: A novel treatment strategy for end-stage and metastatic hepatic alveolar echinococcosis.
- Author
-
Guo Q, Wang ML, Zhong K, Li JL, Jiang TM, Wen H, Aji T, and Shao YM
- Subjects
- Humans, Transplantation, Autologous, Portal Vein surgery, Portal Vein pathology, Hepatectomy, Echinococcosis, Hepatic diagnostic imaging, Echinococcosis, Hepatic surgery, Embolization, Therapeutic
- Published
- 2024
- Full Text
- View/download PDF
7. Assessment of liver function by gadoxetic acid avidity in MRI in a model of rapid liver regeneration in rats.
- Author
-
Heil J, Augath M, Kurtcuoglu V, Hohmann J, Bechstein WO, Olthof P, Schnitzbauer AA, Seebeck P, Schiesser M, Schläpfer M, Beck-Schimmer B, and Schadde E
- Subjects
- Rats, Animals, Rats, Wistar, Liver diagnostic imaging, Liver surgery, Liver blood supply, Hepatectomy methods, Portal Vein diagnostic imaging, Portal Vein surgery, Portal Vein pathology, Magnetic Resonance Imaging, Ligation methods, Liver Regeneration, Liver Neoplasms surgery, Gadolinium DTPA
- Abstract
Background: This animal study investigates the hypothesis of an immature liver growth following ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) by measuring liver volume and function using gadoxetic acid avidity in magnetic resonance imaging (MRI) in models of ALPPS, major liver resection (LR) and portal vein ligation (PVL)., Methods: Wistar rats were randomly allocated to ALPPS, LR or PVL. In contrast-enhanced MRI scans with gadoxetic acid (Primovist®), liver volume and function of the right median lobe (=future liver remnant, FLR) and the deportalized lobes (DPL) were assessed until post-operative day (POD) 5. Liver function
FLR/DPL was defined as the inverse value of time from injection of gadoxetic acid to the blood pool-corrected maximum signal intensityFLR/DPL multiplied by the volumeFLR/DPL ., Results: In ALPPS (n = 6), LR (n = 6) and PVL (n = 6), volumeFLR and functionFLR increased proportionally, except on POD 1. Thereafter, functionFLR exceeded volumeFLR increase in LR and ALPPS, but not in PVL. Total liver function was significantly reduced after LR until POD 3, but never undercuts 60% of its pre-operative value following ALPPS and PVL., Discussion: This study shows for the first time that functional increase is proportional to volume increase in ALPPS using gadoxetic acid avidity in MRI., Competing Interests: Conflict of interest No disclosures of potential conflicts (financial, professional or personal) relevant to the manuscript. Martin Schläpfer and Beatrice Beck-Schimmer have received unrestricted research funds from Sedana Medical, Danderyd, Sweden, and from Roche Diagnostics International, Rotkreuz, Switzerland. Beatrice Beck-Schimmer and Martin Schläpfer have submitted a patent to mitigate the negative effects of surgery and/or anesthesia for patients using medical gases, particularly oxygen (O2) and carbon dioxide (CO2). Beatrice Beck-Schimmer submitted US and EP patent applications for an injectable formulation for the treatment and protection of patients having an inflammatory reaction or an ischemia/reperfusion event., (Copyright © 2023. Published by Elsevier Ltd.)- Published
- 2024
- Full Text
- View/download PDF
8. Liver transplantation and resection in patients with hepatocellular cancer and portal vein tumor thrombosis: Feasible and effective?
- Author
-
Bhangui P
- Subjects
- Humans, Portal Vein diagnostic imaging, Portal Vein surgery, Portal Vein pathology, Retrospective Studies, Treatment Outcome, Liver Neoplasms complications, Liver Neoplasms surgery, Liver Neoplasms pathology, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular pathology, Liver Transplantation adverse effects, Venous Thrombosis diagnostic imaging, Venous Thrombosis etiology, Venous Thrombosis surgery
- Abstract
Patients with locally advanced hepatocellular cancer (HCC) and portal vein tumor thrombosis (PVTT) have a dismal prognosis since limited treatment options are available for them. In recent years, effective systemic therapy, and advances in the understanding of technicalities and effectiveness of ablative therapies especially radiotherapy, have given some hope to prolong survival in them. This review summarized recent evidence in literature regarding the possible role of liver resection (LR) and liver transplantation (LT) in patients with locally advanced HCC and PVTT with no extrahepatic disease. Downstaging therapies have helped make curative resection or LT a reality in selected patients. This review emphasizes on the key points to focus on when considering surgery in these patients, who are usually relegated to palliative systemic therapy alone. Meticulous patient selection based on tumor biology, documented downstaging based on imaging and decrease in tumor marker levels, and an adequate waiting period to demonstrate stable disease, may help obtain satisfactory long-term outcomes post LR or LT in an intention to treat strategy in patients with HCC and PVTT., Competing Interests: Competing interest No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article., (Copyright © 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Portal vein stenting in recurrent or locally advanced peri-hilar cholangiocarcinoma.
- Author
-
De Bellis M, Contro A, Bianco A, Gasparini C, Tripepi M, La Raja M, Alaimo L, Conci S, Campagnaro T, Guglielmi A, Mansueto G, and Ruzzenente A
- Subjects
- Humans, Portal Vein surgery, Treatment Outcome, Constriction, Pathologic etiology, Ascites etiology, Quality of Life, Bile Ducts, Intrahepatic surgery, Bile Ducts, Intrahepatic pathology, Stents adverse effects, Retrospective Studies, Klatskin Tumor pathology, Cholangiocarcinoma surgery, Cholangiocarcinoma pathology, Bile Duct Neoplasms surgery, Bile Duct Neoplasms complications
- Abstract
Background: Recurrent or locally advanced peri-hilar cholangiocarcinoma (PHCC) usually involves the portal vein (PV) leading to significant stenosis. With disease progression, clinical symptoms such as ascites, bleeding, and hepatic insufficiency are usually observed. Little is know about the benefit of PV stenting in relieving the symptoms associated to portal hypertension and allowing anticancer therapies. The aim of this study is to review our experience in PV stenting for PHCC patients., Methods: From 2014 to 2022, data from PHCC patients underwent PV stenting at Verona University Hospital, Italy, were reviewed. The indications were: gastrointestinal bleeding from esophagus-gastric varices, ascites not responsive to medical therapy, severe thrombocytopenia, liver insufficiency (hepatic jaundice, coagulopathy, and/or hyperammoniemia), or asymptomatic high-grade PV stenosis. Cavernous transformation and intrahepatic thrombosis in both sides of the liver were considered contraindication. Systematic anticoagulation therapy was not administered., Results: Technical success was achieved in all 16 (100 %) patients. The improvement of clinical symptoms were observed in 12 (75 %) patients. Anticancer therapy was administrated in 11 (69 %) patients. 2 (13 %) complications were observed: 1 biliary injury and 1 recurrent cholangitis that required a percutaneous trans-hepatic biliary drainage placement. Stent occlusion for tumor progression occurred in 1 patient and a re-stenting procedure was successfully performed. No case of thrombotic stent occlusion was observed during follow up. The 1-year stent patency was 86 % and the median patency period was 8 months (IQR, 4-12)., Conclusion: PV stenting is a feasible and safe palliative treatment that improves clinical condition, allow anticancer therapies, and provide a better quality of life., Competing Interests: Declaration of competing interest All authors state that they have no conflict of interest to disclose., (© 2024 Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
10. Balance of Gata3 and Ramp2 in hepatocytes regulates hepatic vascular reconstitution in postoperative liver regeneration.
- Author
-
Wang B, Shen H, Wei Y, Liu F, Yang Y, Yu H, Fu J, Cui X, Yu T, Xu Y, Liu Y, Dong H, Shen F, Zhou W, Liu H, Chen Y, and Wang H
- Subjects
- Humans, Mice, Animals, Liver Regeneration physiology, Vascular Endothelial Growth Factor A, Retrospective Studies, Endothelial Cells, Liver surgery, Hepatectomy adverse effects, Hepatocytes physiology, Portal Vein surgery, Ligation, GATA3 Transcription Factor, Receptor Activity-Modifying Protein 2, Liver Neoplasms, Liver Failure etiology
- Abstract
Background & Aims: Post-hepatectomy liver failure (PHLF) leads to poor prognosis in patients undergoing hepatectomy, with hepatic vascular reconstitution playing a critical role. However, the regulators of hepatic vascular reconstitution remain unclear. In this study, we aimed to investigate the regulatory mechanisms of hepatic vascular reconstitution and identify biomarkers predicting PHLF in patients undergoing hepatectomy., Methods: Candidate genes that were associated with hepatic vascular reconstitution were screened using adeno-associated virus vectors in Alb-Cre-CRISPR/Cas9 mice subjected to partial hepatectomy. The biological activities of candidate genes were estimated using endothelial precursor transfusion and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) models. The level of candidates was detected in biopsies from patients undergoing ALPPS. Risk factors for PHLF were also screened using retrospective data., Results: Downregulation of Gata3 and upregulation of Ramp2 in hepatocytes promoted the proliferation of liver sinusoidal endothelial cells and hepatic revascularization. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor A (VEGFA) played opposite roles in regulating the migration of endothelial precursors from bone marrow and the formation of new sinusoids after hepatectomy. Gata3 restricted endothelial cell function in patient-derived hepatic organoids, which was abrogated by a Gata3 inhibitor. Moreover, overexpression of Gata3 led to higher mortality in ALPPS mice, which was improved by a PEDF-neutralizing antibody. The expression of Gata3/RAMP and PEDF/VEGFA tended to have a negative correlation in patients undergoing ALPPS. A nomogram incorporating multiple factors, such as serum PEDF/VEGF index, was constructed and could efficiently predict the risk of PHLF., Conclusions: The balance of Gata3 and Ramp2 in hepatocytes regulates the proliferation of liver sinusoidal endothelial cells and hepatic revascularization via changes in the expression of PEDF and VEGFA, revealing potential targets for the prevention and treatment of PHLF., Impact and Implications: In this study, we show that the balance of Gata3 and Ramp2 in hepatocytes regulates hepatic vascular reconstitution by promoting a shift from pigment epithelium-derived factor (PEDF) to vascular endothelial growth factor A (VEGFA) expression during hepatectomy- or ALLPS (associating liver partition and portal vein ligation for staged hepatectomy)-induced liver regeneration. We also identified serum PEDF/VEGFA index as a potential predictor of post-hepatectomy liver failure in patients who underwent hepatectomy. This study improves our understanding of how hepatocytes contribute to liver regeneration and provides new targets for the prevention and treatment of post-hepatectomy liver failure., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
11. Comparing iodized oil with polyvinyl alcohol for portal vein embolization in promoting liver remnant increase before partial hepatectomy.
- Author
-
Wu B, Huang X, Ren Z, Liu Y, Yang X, Wang Y, Chen Q, Dong J, Xiang C, and Zhang Y
- Subjects
- Humans, Hepatectomy adverse effects, Polyvinyl Alcohol, Iodized Oil, Portal Vein surgery, Treatment Outcome, Retrospective Studies, Liver, Hypertrophy etiology, Hypertrophy surgery, Liver Neoplasms surgery, Embolization, Therapeutic adverse effects
- Abstract
Background: To compare the efficacy and safety of iodized oil versus polyvinyl alcohol (PVA) particles in portal vein embolization (PVE) before partial hepatectomy., Methods: From October 2016 to December 2021, 86 patients who planned to undergo hepatectomy after PVE were enrolled, including 61 patients post-PVE with PVA particles + coils and 25 patients post-PVE with iodized oil + coils. All patients underwent CT examination before and 2-3 weeks after PVE to evaluate the future liver remnant (FLR). The intercohort comparison included the degree of liver volume growth, changes in laboratory data, and adverse events., Results: There was no significant difference in the resection rate between the iodized oil group and the PVA particle group (68 % vs. 70 %, p = 0.822). In terms of the degree of hypertrophy (9.52 % ± 13.47 vs. 4.03 % ± 10.55, p = 0.047) and kinetic growth rate (4.07 % ± 5.4 vs. 1.55 % ± 4.63, p = 0.032), the iodized oil group was superior to the PVA group. The PVE operation time in the PVA particle group was shorter than that in the iodized oil group (121. 72 min ± 34.45 vs. 156. 2 min ± 71.58, p = 0.029). There was no significant difference in the degree of hypertrophy between the high bilirubin group and the control group (5.32 % ± 9.21 vs. 6.1 % ± 14.79, p = 0.764). Only 1 patient had a major complication., Conclusions: Compared with PVA particles, iodized oil PVE can significantly increase liver volume and the degree of hypertrophy without any significant difference in safety., Competing Interests: Declaration of competing interest None., (Copyright © 2024 Asian Surgical Association and Taiwan Robotic Surgery Association. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Perioperative outcome and long-term survival for intrahepatic cholangiocarcinoma after portal vein embolization and subsequent resection: A propensity-matched study.
- Author
-
Nevermann N, Bode J, Vischer M, Krenzien F, Lurje G, Pelzer U, Fehrenbach U, Auer TA, Schmelzle M, Pratschke J, and Schöning W
- Subjects
- Humans, Portal Vein surgery, Hepatectomy methods, Bile Ducts, Intrahepatic surgery, Hypertrophy etiology, Hypertrophy surgery, Treatment Outcome, Liver Neoplasms surgery, Liver Neoplasms secondary, Cholangiocarcinoma surgery, Embolization, Therapeutic methods, Bile Duct Neoplasms surgery
- Abstract
Introduction: In view of the high therapeutic value of surgical resection for intrahepatic cholangiocarcinomas (ICC), our study addresses the question of clinical management and outcome in case of borderline resectability requiring hypertrophy induction of the future liver remnant prior to resection., Methods: Clinical data was collected of all primary ICC cases receiving major liver resection with or without prior portal vein embolization (PVE) from a single high-volume center. PVE was performed via a percutaneous transhepatic access. Propensity score matching was performed. Perioperative morbidity was assessed as well as long-term survival with a minimum follow-up of 36 months., Results: No significant difference in perioperative morbidity was seen between the PVE and the control group. For the PVE group, median OS was 28 months vs. 37 months for the control group (p = 0.418), median DFS 18 and 14 months (p = 0.703). Disease progression during hypertrophy was observed in 38% of cases. Here, OS and DFS was reduced to 18 months (p = 0.479) and 6 months (p = 0.013), respectively. In case of positive N-status or multifocal tumor (MF+) OS was also reduced (18 vs. 26 months, p = 0.033; MF+: 9 vs. 36months p = 0.013)., Conclusion: Our results suggest that the surgical therapy in case of borderline resectability offers acceptable results with non-inferior OS rates compared to cases without preoperative hypertrophy induction and comparable oncological features. In the presence of additional risk factors (multifocal tumor, lymph node metastasis, PD during hypertrophy) the OS is notably reduced., Competing Interests: Declaration of competing interest Professor Johann Pratschke reports personal fees or other support outside of the submitted work from Johnson & Johnson, Medtronic, Astellas, CHG Meridian, AFS Medical, Chiesi, Falk Foundation, Neovii, NOGGO, pharma-consult Peterson, La Fource Group, Merck and Promedicis. Professor Moritz Schmelzle reports personal fees or non-financial support outside of the submitted work from Merck Serono GmbH, Bayer AG, ERBE Elektromedizin GmbH, Amgen Inc., Johnson&Johnson Medical GmbH, ERBE Elektromedizin GmbH, Takeda Pharmaceutical Limited, Olympus K.K., Medtronic GmbH, Intuitive Surgical Inc. Drs. Nora Nevermann, Julia Bode, Maxine Vischer, Felix Krenzien, Uwe Pelzer, Uli Fehrenbach, Timo A. Auer and Professor Wenzel Schöning have no conflicts of interest or financial ties to disclose., (© 2023 Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
13. Histologic changes of porcine portal vein anastomosis after electrochemotherapy with bleomycin.
- Author
-
Stupan U, Čemažar M, Trotovšek B, Petrič M, Tomažič A, Gašljević G, Ranković B, Seliškar A, Plavec T, Sredenšek J, Plut J, Štukelj M, Lampreht Tratar U, Jesenko T, Nemec Svete A, Serša G, and Đokić M
- Subjects
- Animals, Swine, Bleomycin, Portal Vein surgery, Anastomosis, Surgical, Electrochemotherapy, Pancreatic Neoplasms drug therapy
- Abstract
Electrochemotherapy (ECT
1 ) is used for treatment of unresectable abdominal malignancies. This study aims to show that ECT of porcine portal vein anastomosis is safe and feasible in order to extend the indications for margin attenuation after resection of locally advanced pancreatic carcinoma. No marked differences were found between the control group and ECT treated groups. Electroporation thus caused irreversible damage to the vascular smooth muscle cells in tunica media that could bedue to the narrow irreversible electroporation zone that may occur near the electrodes, or due to vasa vasorum thrombosis in the tunica externa. Based on the absence of vascular complications, and similar histological changes in lienal veinanastomosis, we can conclude that ECT of portal vein anastomosis is safe and feasible., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
14. EORTC 1409 GITCG/ESSO 01 - A prospective colorectal liver metastasis database for borderline or initially unresectable diseases (CLIMB): Lessons learnt from real life. From paradigm to unmet need.
- Author
-
Collienne M, Neven A, Caballero C, Kataoka K, Carrion-Alvarez L, Nilsson H, Désolneux G, Rivoire M, Ruers T, Gruenberger T, Protic M, Troisi RI, Primavesi F, Staettner S, Rahbari N, Schnitzbauer A, Malik H, Swijnenburg RJ, Mauer M, Ducreux M, and Evrard S
- Subjects
- Humans, Treatment Outcome, Prospective Studies, Hepatectomy methods, Ligation, Postoperative Complications etiology, Portal Vein surgery, Liver pathology, Colorectal Neoplasms pathology, Liver Neoplasms secondary
- Abstract
Aim: Multidisciplinary management of metastatic colorectal liver metastases (CRLM) is still challenging. To assess postoperative complications in initially unresectable or borderline resectable CRLM, the prospective EORTC-1409 ESSO 01-CLIMB trial capturing 'real-life data' of European centres specialized in liver surgery was initiated., Material and Methods: A total of 219 patients were registered between May 2015 and January 2019 from 15 centres in nine countries. Eligible patients had borderline or initially unresectable CRLM assessed by pre-operative multidisciplinary team discussion (MDT). Primary endpoints were postoperative complications, 30-day and 90-days mortality post-surgery, and quality indicators. We report the final results of the 151 eligible patients that underwent at least one liver surgery., Results: Perioperative chemotherapy with or without targeted treatment were administered in 100 patients (69.4%). One stage resection (OSR) was performed in 119 patients (78.8%). Two stage resections (TSR, incl. Associating Liver Partition and Portal Vein Ligation for Staged hepatectomy (ALPPS)) were completed in 24 out of 32 patients (75%). Postoperative complications were reported in 55.5% (95% CI: 46.1-64.6%), 64.0% (95% CI: 42.5-82%), and 100% (95% CI: 59-100%) of the patients in OSR, TSR and ALPPS, respectively. Post-hepatectomy liver failure occurred in 6.7%, 20.0%, and 28.6% in OSR, TSR, and ALPPS, respectively. In total, four patients (2.6%) died after surgery., Conclusion: Across nine countries, OSR was more often performed than TSR and tended to result in less postoperative complications. Despite many efforts to register patients across Europe, it is still challenging to set up a prospective CRLM database., Competing Interests: Declaration of competing interests Carmela Caballero reports a relationship with European Society of Surgical Oncology that includes: non-financial support. Michel Ducreux reports a relationship with Roche that includes: consulting or advisory, funding grants, and speaking and lecture fees. Michel Ducreux reports a relationship with Merck Serono that includes: consulting or advisory, funding grants, and speaking and lecture fees. Michel Ducreux reports a relationship with Amgen that includes: consulting or advisory. Michel Ducreux reports a relationship with Sanofi that includes: consulting or advisory and speaking and lecture fees. Michel Ducreux reports a relationship with Bayer that includes: consulting or advisory and speaking and lecture fees. Michel Ducreux reports a relationship with Lilly that includes: consulting or advisory and speaking and lecture fees. Michel Ducreux reports a relationship with Celgene that includes: consulting or advisory and speaking and lecture fees. Michel Ducreux reports a relationship with Servier that includes: consulting or advisory and speaking and lecture fees. Michel Ducreux reports a relationship with Ipsen that includes: consulting or advisory. Michel Ducreux reports a relationship with Pierre Fabre that includes: consulting or advisory. Michel Ducreux reports a relationship with Pfizer that includes: funding grants. Serge Evrard represents as study coordinator the EORTC study team. Carmela Caballero declares that she has a (uncompensated) leadership position at the European Society of Surgical Oncology. Michel Ducreux's wife is head of the oncology business unit at Sandoz France., (© 2023 Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
15. A surgical technique using the gastroepiploic vein for portal inflow restoration in living donor liver transplantation in a patient with diffuse portomesenteric thrombosis.
- Author
-
Kim SH, Moon DB, Kang WH, Jung DH, and Lee SG
- Subjects
- Humans, Living Donors, Liver blood supply, Portal Vein diagnostic imaging, Portal Vein surgery, Liver Transplantation methods, Thrombosis diagnostic imaging, Thrombosis etiology, Thrombosis surgery
- Published
- 2023
- Full Text
- View/download PDF
16. Impact of rapid hypertrophy of tourniquet associating liver partition and portal vein ligation in the tumor progression pathways compared to two stage hepatectomy in patients with colorectal liver metastases.
- Author
-
Lopez-Lopez V, Martínez-Caceres C, Gomez-Valles P, Cruz J, Caballero-Illanes A, Brusadin R, López-Conesa A, Pérez M, Miura K, de la Peña-Moral J, and Robles-Campos R
- Subjects
- Humans, Hepatectomy methods, Portal Vein surgery, Portal Vein pathology, Tourniquets, Liver surgery, Hypertrophy pathology, Hypertrophy surgery, Thyrotropin, Ligation, Treatment Outcome, Colorectal Neoplasms pathology, Liver Neoplasms
- Abstract
Background: It is not known if the inflammatory phenomena related to highly accelerated regeneration activate any signaling pathways that are associated with a major stimulus to colorectal liver metastases (CRLM) disease in tourniquet associating liver partition and portal vein ligation for staged hepatectomy (T-ALPPS) compared to two stage hepatectomy (TSH)., Methods: Between January 2012 and April 2018, we prospectively performed biopsies from future liver remnant and deportalized lobe in CRLM patients undergoing T-ALPPS in both stages. Immunohistopathological analysis was performed on the above tissue samples and compared to biopsy samples from patients who underwent TSH for CRLM at our center between September 2000 and August 2011., Results: A total of 42 patients (20 TSH and 22 T-ALPPS) were included. There were no differences in the rates of recurrence, overall survival or any of the factors analyzed relating to tumor progression between stages 1 and 2. Regarding the anti-tumor effect, there was a significant reduction in the number of T-CD8 infiltrates in the second stage of TSH (12.5 vs. 5.5, p = 0.02)., Conclusion: The results suggest that liver regeneration with T-ALPPS does not induce higher tumor progression or significant immunological changes in the tumor environment when compared to classical TSH., Competing Interests: Conflict of interest None to declare., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
17. Do the stent blind insertion into the main portal vein (MPV) and stent diameter influence the surgical outcome of the transjugular intrahepatic portosystemic shunt (TIPS)?
- Author
-
Jiang L, Han H, Yang J, Fang R, Xin Y, Chen Q, Yao J, and Li Z
- Subjects
- Humans, Portal Vein surgery, Stents adverse effects, Treatment Outcome, Portasystemic Shunt, Transjugular Intrahepatic adverse effects, Portasystemic Shunt, Transjugular Intrahepatic methods, Hypertension, Portal surgery
- Abstract
Transjugular intrahepatic portosystemic shunt (TIPS) surgery is a clinical intervention to treat portal hypertension (PH) by deploying a covered stent to establish a shunt path for the portal vein (PV) system, and proper surgical strategy is of great importance to balance the shunt effect and the risk of complications. To understand the clinical strategies of the stent blind insertion and stent selection in clinic, this study investigated the effects of varying stent insertion positions and diameters on the PV hemodynamics and the shunt effect by computational fluid dynamics (CFD) analysis of five post-TIPS subjects. The results showed that the successful TIPS surgeries of the five PH subjects were confirmed by quantifying their pressure drops. The stent insertion positions at the main portal vein (MPV) slightly affected the clinically concerned hemodynamic indexes (i.e., MPV pressure, stent-outlet velocity) and the shunt index (SI). This indicated that the position of the stent going into the MPV may not need to be deliberately selected. Moreover, the covered stents with 6 mm and 8 mm diameters slightly influenced the hemodynamics as well, but the large-diameter stent better improved the shunt effect compared to the small-diameter one. Despite this, the 6 mm stent was suggested thanks to the higher risk of the hepatic encephalopathy (HE) observed in clinic, which indicated the excessive shunt of the 8 mm stent. The current work revealed the effects of different TIPS strategies on the surgical outcome, and could be useful for potential clinical practices., Competing Interests: Declaration of competing interest The authors declare that there are no conflicts of interest., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. Reconstruction for complex portal vein thrombosis - Anatomical if possible.
- Author
-
Durán M, Alfarah J, Hann A, and Perera MTPR
- Subjects
- Humans, Portal Vein surgery, Venous Thrombosis etiology, Venous Thrombosis surgery, Liver Diseases
- Published
- 2023
- Full Text
- View/download PDF
19. Reply to: "Reconstruction for complex portal vein thrombosis - Anatomical if possible".
- Author
-
Fundora Y, Hessheimer AJ, and Fondevila C
- Subjects
- Humans, Portal Vein surgery, Venous Thrombosis, Liver Diseases
- Published
- 2023
- Full Text
- View/download PDF
20. Pancreatectomy with venous vascular resection for pancreatic cancer: Impact of types of vein resection on timing and pattern of recurrence.
- Author
-
Tamburrino D, Belfiori G, Andreasi V, Provinciali L, Cerchione R, De Stefano F, Fermi F, Gasparini G, Pecorelli N, Partelli S, Crippa S, and Falconi M
- Subjects
- Humans, Pancreatectomy methods, Retrospective Studies, Portal Vein surgery, Portal Vein pathology, Pancreatic Neoplasms, Pancreatic Neoplasms pathology, Carcinoma, Pancreatic Ductal pathology
- Abstract
Introduction: Few studies analysed the impact of different venous resection techniques on recurrence in patients with pancreatic ductal adenocarcinoma (PDAC). Primary aim was to compare local recurrence rate and disease-free survival (DFS) between patients who underwent pancreatectomy with tangential versus segmental resection of portal vein/superior mesenteric vein., Materials and Methods: All consecutive patients who underwent pancreatectomy with venous resection for PDAC between 2009 and 2019 were included. A propensity score matching (PSM) was used to reduce the effect of treatment selection bias., Results: Overall, 120 patients (68%) underwent pancreatectomy with tangential venous resection and 57 patients (32%) were submitted to pancreatectomy with segmental venous resection. After a median follow-up of 24 months, local recurrence was comparable between the two groups (tangential: n = 32/120, 26.7% versus segmental: n = 10/57, 17.5%; p = 0.58). The median DFS was 17 months (IQR 9-31) in patients who underwent tangential resection, as compared to 12 months (IQR 5-21) in those who underwent segmental resection (p = 0.049). After PSM (n = 106), the median DFS was 18 months (IQR 9-26) in the tangential resection group, and 12 months (IQR 5-21) in the segmental resection group (p = 0.17). In the PSM population, lymph node ratio (HR 4.83; p = 0.028) and tumor size >25 mm (HR 3.26; p = 0.007) were identified as determinants of local recurrence., Conclusion: Tangential venous resections are not associated with a higher rate of local recurrence. Long-term outcomes are more related to tumors characteristics than to venous resection techniques. A step-up approach to vein resection, with tangential resection being performed whenever technically feasible, should be strongly encouraged., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
21. Caudate lobe-sparing subtotal hepatectomy as treatment for extensive intrahepatic arterioportal fistula.
- Author
-
Tang R, Wu GD, Li A, Yu LH, Tong X, Yan J, and Lu Q
- Subjects
- Humans, Hepatectomy, Portal Vein diagnostic imaging, Portal Vein surgery, Hepatic Artery diagnostic imaging, Hepatic Artery surgery, Carcinoma, Hepatocellular surgery, Liver Neoplasms surgery, Fistula surgery
- Published
- 2023
- Full Text
- View/download PDF
22. Indocyanine green staining via hyperselective portal vein angiographic approach for laparoscopic S8 anatomical subsegmentectomy.
- Author
-
Huang CC, Hsieh CH, Siow TF, and Chen KH
- Subjects
- Humans, Indocyanine Green, Portal Vein diagnostic imaging, Portal Vein surgery, Staining and Labeling, Hepatectomy, Optical Imaging, Carcinoma, Hepatocellular surgery, Liver Neoplasms surgery, Laparoscopy
- Abstract
Competing Interests: Declaration of competing interest The authors have no conflicts of interest or financial ties to disclose.
- Published
- 2023
- Full Text
- View/download PDF
23. Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
- Author
-
Cao Y, Tang H, Hu B, Zhang W, Wan T, Han J, Jiao T, Li J, Li X, Yang Z, Liu Z, Hu M, Duan W, Li C, Zhao Z, and Lu S
- Subjects
- Humans, Propensity Score, Retrospective Studies, Portal Vein surgery, Portal Vein pathology, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular surgery, Liver Neoplasms complications, Liver Neoplasms surgery, Venous Thrombosis etiology, Venous Thrombosis surgery, Venous Thrombosis pathology
- Abstract
Background: Salvage surgery after conversion therapy with a combination of tyrosine kinase inhibitor and anti-programmed death-1 antibody has shown improved survival benefits in patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). We aimed to compare the survival benefits in a retrospective cohort of patients with HCC with PVTT who underwent salvage surgery after conversion therapy and surgery alone., Methods: From January 2015 to October 2021, we selected patients diagnosed with HCC with PVTT who underwent liver resection at Chinese PLA General Hospital. The primary endpoint in the comparison of survival benefits between conversion therapy and surgery-alone groups was recurrence-free survival. Propensity score matching was applied to reduce any potential bias in the study., Results: The 6-, 12-, and 24-month recurrence-free survival rates in the conversion and surgery alone groups were 80.3% vs 36.5%, 65.4% vs 29.4%, and 56% vs 21%, respectively. On multivariable Cox regression analyses, conversion therapy significantly reduced HCC-related mortality and HCC recurrence rates compared with surgery alone., Conclusions: For patients with HCC with PVTT, surgery after conversion therapy is in relationship with increased survival in comparison with surgery alone., (Copyright © 2023 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Analysis of nursing points for complications after portal venous reconstruction in allogeneic graft.
- Author
-
Pan B, Wei W, Han G, and Wang Y
- Subjects
- Humans, Allografts, Retrospective Studies, Portal Vein surgery, Venous Thrombosis etiology
- Abstract
Competing Interests: Declaration of competing interest No potential conflict of interest was reported by the author(s).
- Published
- 2023
- Full Text
- View/download PDF
25. Simultaneous portal and hepatic vein embolization is better than portal embolization or ALPPS for hypertrophy of future liver remnant before major hepatectomy: A systematic review and network meta-analysis.
- Author
-
Gavriilidis P, Marangoni G, Ahmad J, and Azoulay D
- Subjects
- Humans, Hepatectomy methods, Hepatic Veins pathology, Network Meta-Analysis, Treatment Outcome, Liver pathology, Portal Vein surgery, Portal Vein pathology, Hepatomegaly etiology, Hypertrophy pathology, Hypertrophy surgery, Ligation, Liver Neoplasms pathology, Embolization, Therapeutic adverse effects, Embolization, Therapeutic methods
- Abstract
Background: Post-hepatectomy liver failure (PHLF) is the Achilles' heel of hepatic resection for colorectal liver metastases. The most commonly used procedure to generate hypertrophy of the functional liver remnant (FLR) is portal vein embolization (PVE), which does not always lead to successful hypertrophy. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has been proposed to overcome the limitations of PVE. Liver venous deprivation (LVD), a technique that includes simultaneous portal and hepatic vein embolization, has also been proposed as an alternative to ALPPS. The present study aimed to conduct a systematic review as the first network meta-analysis to compare the efficacy, effectiveness, and safety of the three regenerative techniques., Data Sources: A systematic search for literature was conducted using the electronic databases Embase, PubMed (MEDLINE), Google Scholar and Cochrane., Results: The time to operation was significantly shorter in the ALPPS cohort than in the PVE and LVD cohorts by 27 and 22 days, respectively. Intraoperative parameters of blood loss and the Pringle maneuver demonstrated non-significant differences between the PVE and LVD cohorts. There was evidence of a significantly higher FLR hypertrophy rate in the ALPPS cohort when compared to the PVE cohort, but non-significant differences were observed when compared to the LVD cohort. Notably, the LVD cohort demonstrated a significantly better FLR/body weight (BW) ratio compared to both the ALPPS and PVE cohorts. Both the PVE and LVD cohorts demonstrated significantly lower major morbidity rates compared to the ALPPS cohort. The LVD cohort also demonstrated a significantly lower 90-day mortality rate compared to both the PVE and ALPPS cohorts., Conclusions: LVD in adequately selected patients may induce adequate and profound FLR hypertrophy before major hepatectomy. Present evidence demonstrated significantly lower major morbidity and mortality rates in the LVD cohort than in the ALPPS and PVE cohorts., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2023
- Full Text
- View/download PDF
26. Portal vein reconstruction using an autologous left renal vein-graft in living-related right-lobe liver transplantation.
- Author
-
Hosokawa I, Kuboki S, Miyazaki M, and Ohtsuka M
- Subjects
- Humans, Renal Veins surgery, Liver surgery, Hepatectomy, Living Donors, Hepatic Veins surgery, Portal Vein surgery, Liver Transplantation
- Abstract
Competing Interests: Declaration of competing interest The authors declared no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
27. Interventional treatment for portal vein complications utilizing a hybrid operating room after liver transplantation.
- Author
-
Hakoda H, Akamatsu N, Shibata E, Takao H, Ichida A, Kawaguchi Y, Kaneko J, Abe O, and Hasegawa K
- Subjects
- Humans, Portal Vein diagnostic imaging, Portal Vein surgery, Operating Rooms, Treatment Outcome, Constriction, Pathologic etiology, Constriction, Pathologic surgery, Stents adverse effects, Liver Transplantation adverse effects, Liver Transplantation methods, Venous Thrombosis diagnostic imaging, Venous Thrombosis etiology, Venous Thrombosis therapy
- Abstract
Background: Vascular complications after liver transplantation (LT) can be lethal and require immediate treatment to prevent graft failure. Nowadays, with interventional radiology (IR), approaches such as the percutaneous transhepatic (PTH) and transileocolic venous (TIC), have become major treatment options. We reviewed the safety and efficacy of a hybrid operating room (OR) for portal vein complications after LT., Methods: Patients who underwent IR for post-LT vascular complications in the hybrid OR from May 2014 to May 2022 were enrolled. Patients who underwent post-LT IR in conventional angiography rooms were excluded., Results: Nine patients developed portal vein complications; eight after living donor LT and one after deceased donor LT. Six patients had portal vein stenosis, two had portal vein thrombosis, and one had both. In the hybrid OR, PTH and TIC were used in five and three cases, respectively. The Rendezvous technique was used in one case. Angioplasty was performed in all patients. A stent was placed in four patients. The portal venous pressure gradient across the stenotic site significantly decreased after IR (P &= 0.031). The IR success rate in the hybrid OR was 100%., Conclusion: The hybrid OR enables us to accomplish IR for post-LT vascular complications safely and effectively., (Copyright © 2023 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
28. Laparoscopic pancreaticoduodenectomy with portal or superior mesenteric vein resection and reconstruction for pancreatic cancer: A single-center experience.
- Author
-
Ma MJ, Cheng H, Chen YS, Yu XJ, and Liu C
- Subjects
- Humans, Pancreaticoduodenectomy adverse effects, Pancreaticoduodenectomy methods, Mesenteric Veins diagnostic imaging, Mesenteric Veins surgery, Mesenteric Veins pathology, China, Portal Vein surgery, Portal Vein pathology, Postoperative Complications surgery, Retrospective Studies, Pancreatic Neoplasms, Pancreatic Neoplasms pathology, Laparoscopy adverse effects, Laparoscopy methods
- Abstract
Background: Open pancreaticoduodenectomy (OPD) with portal or superior mesenteric vein resection and reconstruction has been applied in pancreatic cancer patients with tumor infiltration or adherence. However, it is controversial whether laparoscopic pancreaticoduodenectomy (LPD) with major vascular resection and reconstruction is feasible. This study aimed to evaluate the safety and feasibility of LPD with major vascular resection compared with OPD with major vascular resection., Methods: We reviewed data for all pancreatic cancer patients undergoing LPD or OPD with vascular resection at Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, between February 2018 and May 2022. We compared the preoperative, intraoperative, and postoperative clinicopathological data of the two groups to conduct a comprehensive evaluation of LPD with major vascular resection., Results: A total of 63 patients underwent pancreaticoduodenectomy (PD) with portal or superior mesenteric vein resection and reconstruction, including 25 LPDs and 38 OPDs. The LPD group had less intraoperative blood loss (200 vs. 400 mL, P < 0.001), lower proportion of intraoperative blood transfusion (16.0% vs. 39.5%, P = 0.047), longer operation time (390 vs. 334 min, P = 0.004) and shorter postoperative hospital stay (11 vs. 14 days, P = 0.005). There was no perioperative death in all patients. There was no significant difference in the incidence of total postoperative complications, grade B/C postoperative pancreatic fistula, delayed gastric emptying and abdominal infection between the two groups. No postpancreatectomy hemorrhage nor bile leakage occurred during perioperative period. There was no significant difference in R0 resection rate and number of lymph nodes harvested between the two groups. Patency of reconstructed vessels in the two groups were 96.0% and 92.1%, respectively (P = 0.927)., Conclusions: LPD with portal or superior mesenteric vein resection and reconstruction was safe, feasible and oncologically acceptable for selected patients with pancreatic cancer, and it can achieve similar or even better perioperative results compared to open approach., Competing Interests: Competing interest No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article., (Copyright © 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
29. Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis.
- Author
-
Fundora Y, Hessheimer AJ, Del Prete L, Maroni L, Lanari J, Barrios O, Clarysse M, Gastaca M, Barrera Gómez M, Bonadona A, Janek J, Boscà A, Álamo Martínez JM, Zozaya G, López Garnica D, Magistri P, León F, Magini G, Patrono D, Ničovský J, Hakeem AR, Nadalin S, McCormack L, Palacios P, Zieniewicz K, Blanco G, Nuño J, Pérez Saborido B, Echeverri J, Bynon JS, Martins PN, López López V, Dayangac M, Lodge JPA, Romagnoli R, Toso C, Santoyo J, Di Benedetto F, Gómez-Gavara C, Rotellar F, Gómez-Bravo MÁ, López Andújar R, Girard E, Valdivieso A, Pirenne J, Lladó L, Germani G, Cescon M, Hashimoto K, Quintini C, Cillo U, Polak WG, and Fondevila C
- Subjects
- Humans, Middle Aged, Portal Vein surgery, Ascites complications, Gastrointestinal Hemorrhage, Severity of Illness Index, Liver Transplantation methods, End Stage Liver Disease complications, Esophageal and Gastric Varices complications, Hypertension, Portal complications, Hypertension, Portal surgery, Venous Thrombosis etiology, Venous Thrombosis surgery
- Abstract
Background & Aims: Complex portal vein thrombosis (PVT) is a challenge in liver transplantation (LT). Extra-anatomical approaches to portal revascularization, including renoportal (RPA), left gastric vein (LGA), pericholedochal vein (PCA), and cavoportal (CPA) anastomoses, have been described in case reports and series. The RP4LT Collaborative was created to record cases of alternative portal revascularization performed for complex PVT., Methods: An international, observational web registry was launched in 2020. Cases of complex PVT undergoing first LT performed with RPA, LGA, PCA, or CPA were recorded and updated through 12/2021., Results: A total of 140 cases were available for analysis: 74 RPA, 18 LGA, 20 PCA, and 28 CPA. Transplants were primarily performed with whole livers (98%) in recipients with median (IQR) age 58 (49-63) years, model for end-stage liver disease score 17 (14-24), and cold ischemia 431 (360-505) minutes. Post-operatively, 49% of recipients developed acute kidney injury, 16% diuretic-responsive ascites, 9% refractory ascites (29% with CPA, p <0.001), and 10% variceal hemorrhage (25% with CPA, p = 0.002). After a median follow-up of 22 (4-67) months, patient and graft 1-/3-/5-year survival rates were 71/67/61% and 69/63/57%, respectively. On multivariate Cox proportional hazards analysis, the only factor significantly and independently associated with all-cause graft loss was non-physiological portal vein reconstruction in which all graft portal inflow arose from recipient systemic circulation (hazard ratio 6.639, 95% CI 2.159-20.422, p = 0.001)., Conclusions: Alternative forms of portal vein anastomosis achieving physiological portal inflow (i.e., at least some recipient splanchnic blood flow reaching transplant graft) offer acceptable post-transplant results in LT candidates with complex PVT. On the contrary, non-physiological portal vein anastomoses fail to resolve portal hypertension and should not be performed., Impact and Implications: Complex portal vein thrombosis (PVT) is a challenge in liver transplantation. Results of this international, multicenter analysis may be used to guide clinical decisions in transplant candidates with complex PVT. Extra-anatomical portal vein anastomoses that allow for at least some recipient splanchnic blood flow to the transplant allograft offer acceptable results. On the other hand, anastomoses that deliver only systemic blood flow to the allograft fail to resolve portal hypertension and should not be performed., (Copyright © 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
30. Two stage hepatectomy (TSH) versus ALPPS for initially unresectable colorectal liver metastases: A systematic review and meta-analysis.
- Author
-
Díaz Vico T, Granero Castro P, Alcover Navarro L, Suárez Sánchez A, Mihic Góngora L, Montalvá Orón EM, Maupoey Ibáñez J, Truán Alonso N, González-Pinto Arrillaga I, and Granero Trancón JE
- Subjects
- Humans, Ligation methods, Liver pathology, Liver surgery, Portal Vein surgery, Postoperative Complications surgery, Treatment Outcome, Colorectal Neoplasms pathology, Hepatectomy methods, Liver Neoplasms secondary, Liver Neoplasms surgery
- Abstract
Background: Although numerous comparisons between conventional Two Stage Hepatectomy (TSH) and Associating Liver Partition and Portal Vein Ligation for staged hepatectomy (ALPPS) have been reported, the heterogeneity of malignancies previously compared represents an important source of selection bias. This systematic review and meta-analysis aimed to compare perioperative and oncological outcomes between TSH and ALPPS to treat patients with initially unresectable colorectal liver metastases (CRLM)., Methods: Main electronic databases were searched using medical subject headings for CRLM surgically treated with TSH or ALPPS. Patients treated for primary or secondary liver malignancies other than CRLM were excluded., Results: A total of 335 patients from 5 studies were included. Postoperative major complications were higher in the ALPPS group (relative risk [RR] 1.46, 95% confidence interval [CI] 1.04-2.06, I
2 = 0%), while no differences were observed in terms of perioperative mortality (RR 1.53, 95% CI 0.64-3.62, I2 = 0%). ALPPS was associated with higher completion of hepatectomy rates (RR 1.32, 95% CI 1.09-1.61, I2 = 85%), as well as R0 resection rates (RR 1.61, 95% CI 1.13-2.30, I2 = 40%). Nevertheless, no significant differences were achieved between groups in terms of overall survival (OS) (RR 0.93, 95% CI 0.68-1.27, I2 = 52%) and disease-free survival (DFS) (RR 1.08, 95% CI 0.47-2.49, I2 = 54%), respectively., Conclusion: ALPPS and TSH to treat CRLM seem to have comparable operative risks in terms of mortality rates. No definitive conclusions regarding OS and DFS can be drawn from the results., Competing Interests: Declaration of competing interest The authors declare that they have no conflict of interest., (Copyright © 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
31. Modified ALPPS as an individual rescue treatment strategy for resection of Klatskin tumors.
- Author
-
Stavrou GA, Kardassis D, Blatt LA, Gharbi A, and Donati M
- Subjects
- Humans, Liver pathology, Hepatectomy, Portal Vein surgery, Portal Vein pathology, Ligation, Treatment Outcome, Klatskin Tumor surgery, Klatskin Tumor pathology, Bile Duct Neoplasms surgery, Bile Duct Neoplasms pathology, Liver Neoplasms surgery, Liver Neoplasms pathology
- Abstract
Competing Interests: Competing interest No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
- Published
- 2023
- Full Text
- View/download PDF
32. Laparoscopic central hepatectomy with right anterior portal vein thrombectomy for hepatocellular carcinoma.
- Author
-
Siow TF, Lin YT, Chang YJ, and Chen KH
- Subjects
- Humans, Hepatectomy, Portal Vein surgery, Portal Vein pathology, Thrombectomy, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular pathology, Liver Neoplasms surgery, Liver Neoplasms pathology, Laparoscopy
- Published
- 2023
- Full Text
- View/download PDF
33. Surgical treatment of multiple splenic artery aneurysms with portal vein occlusion.
- Author
-
Wu L, Li F, Sun X, Liu Z, and Zheng Y
- Subjects
- Humans, Splenic Artery diagnostic imaging, Splenic Artery surgery, Portal Vein diagnostic imaging, Portal Vein surgery, Aneurysm diagnostic imaging, Aneurysm surgery
- Published
- 2023
- Full Text
- View/download PDF
34. Letter to editor: How to select eligible hepatocellular carcinoma patients with portal vein tumor thrombus for deceased donor liver transplantation?
- Author
-
Zhang J and Yang H
- Subjects
- Humans, Portal Vein surgery, Portal Vein pathology, Living Donors, Treatment Outcome, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular pathology, Liver Transplantation, Liver Neoplasms complications, Liver Neoplasms surgery, Liver Neoplasms pathology, Thrombosis etiology, Thrombosis surgery
- Abstract
Competing Interests: Declaration of competing interest Possible Conflic t of Interest: No.
- Published
- 2022
- Full Text
- View/download PDF
35. Reply to 'How to select eligible hepatocellular carcinoma patients with portal vein tumor thrombus for deceased donor liver transplantation?'
- Author
-
Yu J, Lu D, and Xu X
- Subjects
- Humans, Portal Vein surgery, Portal Vein pathology, Living Donors, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular pathology, Liver Transplantation, Liver Neoplasms complications, Liver Neoplasms surgery, Liver Neoplasms pathology, Thrombosis etiology, Thrombosis surgery
- Abstract
Competing Interests: Declaration of competing interest The authors declare there is no conflicts of interest regarding the publication of this paper.
- Published
- 2022
- Full Text
- View/download PDF
36. Incidence, risk factors, and outcomes of jejunal varix of the afferent loop after pancreatoduodenectomy.
- Author
-
D'Silva M, Yoon YS, Lee JS, Cho JY, Lee HW, Lee B, Kim M, and Han HS
- Subjects
- Humans, Constriction, Pathologic complications, Gastrointestinal Hemorrhage etiology, Stents adverse effects, Portal Vein surgery, Risk Factors, Esophageal and Gastric Varices, Varicose Veins diagnostic imaging, Varicose Veins epidemiology, Varicose Veins surgery
- Abstract
Background: Jejunal varix is a concerning late complication after pancreatoduodenectomy (PD) due to the risk of recurrent and intractable bleeding. Our aim was to investigate the incidence, risk factors, and outcomes of jejunal varix after PD., Methods: A total of 709 patients who underwent PD between 2007 and 2017 were included. Preoperative and postoperative CT images were reviewed to evaluate the development of portal vein (PV) stenosis (≥50%) and jejunal varices., Results: Jejunal varix developed in 83 (11.7%) patients at a median of 12 months after PD. Eighteen (21.7%) patients experienced variceal bleeding. PV stenosis (P < 0.001; odds ratio [OR] 33.2, 95% confidence interval [CI] 15.6-66.7) and PV/superior mesenteric vein resection (P = 0.028; OR 2.3, 95% CI 1.1-4.7) were independent risk factors for jejunal varix. Of the nine patients who underwent stent placement for PV stenosis before the formation of jejunal varices, none experienced variceal bleeding. By contrast, 18 (27.3%) of the 135 patients without PV stent placement experienced at least one episode of variceal bleeding., Conclusions: The incidence of jejunal varix was substantial after PD. PV stenosis was a strong risk factor for jejunal varix. Early PV stent placement and maintaining stent patency could reduce the risk of variceal bleeding in patients with PV stenosis., Competing Interests: Conflict of Interest The authors have no conflicts of interest to declare, (Copyright © 2022 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
37. Should associating liver partition and portal vein ligation for staged hepatectomy be applied to hepatitis B virus-related hepatocellular carcinoma patients with cirrhosis? A multi-center study.
- Author
-
Lv JH, Chen WZ, Li YN, Wang JX, Fu YK, Zeng ZX, Wu JY, Wang SJ, Huang XX, Huang LM, Huang RF, Wei YG, and Yan ML
- Subjects
- Humans, Portal Vein surgery, Portal Vein pathology, Hepatitis B virus, Treatment Outcome, Hepatectomy adverse effects, Hepatectomy methods, Ligation, Liver Cirrhosis pathology, Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic adverse effects
- Abstract
Background: It is unclear whether associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) can be performed in hepatitis B virus-related hepatocellular carcinoma (HCC) patients with cirrhosis. We explored the efficacy of ALPPS in HCC patients., Methods: Data of 54 patients who underwent ALPPS between August 2014 and July 2020 at three centers were collected. Adverse factors affecting their prognosis were analyzed and subsequently compared with 184 patients who underwent transcatheter arterial chemoembolization (TACE)., Results: Overall survival rates of the ALPPS group at 1, 3, and 5 years were 70.6%, 38.4%, and 31.7%, respectively; corresponding disease-free survival rates were 50.5%, 22.4%, and 19.2%, respectively. The ALPPS group had a significantly greater long-term survival rate than the TACE group (before propensity score matching, P < 0.001; after propensity score matching, P = 0.002). Multivariate analysis demonstrated that multifocal lesions (P = 0.018) and macroscopic vascular invasion (P = 0.001) were prognostic factors for HCC patients who underwent ALPPS. After the propensity score matching, the multifocal lesions (P = 0.031), macroscopic vascular invasion (P = 0.003), and treatment type (ALPPS/TACE) (P = 0.026) were the factors adversely affecting the prognosis of HCC patients., Conclusion: ALPPS was feasible in hepatitis B virus-related HCC patients with cirrhosis and resulted in better survival than TACE., (Copyright © 2022 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
38. The "Hand as Foot" teaching method in anatomical variants of the hepatic portal vein.
- Author
-
Fan S, Zhao R, Zhang X, and Cao X
- Subjects
- Anatomic Variation, Hepatectomy, Humans, Hepatic Veins, Portal Vein surgery
- Abstract
Competing Interests: Declaration of competing interest All authors have no potential conflicts of interest to disclose.
- Published
- 2022
- Full Text
- View/download PDF
39. Patency rates of hepatic arterial resection and revascularization in locally advanced pancreatic cancer.
- Author
-
Alva-Ruiz R, Abdelrahman AM, Starlinger PP, Yonkus JA, Moravec DN, Busch JJ, Fleming CJ, Andrews JC, Mendes BC, Colglazier JJ, Smoot RL, Cleary SP, Nagorney DM, Kendrick ML, and Truty MJ
- Subjects
- Humans, Hepatic Artery surgery, Hepatic Artery pathology, Treatment Outcome, Pancreatectomy adverse effects, Portal Vein surgery, Retrospective Studies, Pancreatic Neoplasms pathology, Adenocarcinoma surgery, Arterial Occlusive Diseases
- Abstract
Background: Arterial resection (AR) for pancreatic adenocarcinoma is increasingly considered at specialized centers. We aimed to examine the incidence, risk factors, and outcomes of hepatic artery (HA) occlusion after revascularization., Methods: We included patients undergoing HA resection with interposition graft (IG) or primary end-to-end anastomoses (EE). Complete arterial occlusion (CAO) was defined as "early" (EO) or "late" (LO) before/after 90 days respectively. Kaplan-Meier and change-point analysis for CAO was performed., Results: HA resection was performed in 108 patients, IG in 61% (66/108) and EE in 39% (42/108). An equal proportion (50%) underwent HA resection alone or in combination with celiac and/or superior mesenteric artery. CAO was identified in 18% of patients (19/108) with arterial IG least likely to occlude (p=0.019). Hepatic complications occurred in 42% (45/108) and correlated with CAO, symptomatic patients, venous resection, and postoperative portal venous patency. CAO-related operative mortality was 4.6% and significantly higher in EO vs LO (p = 0.046). Median CAO occlusion was 126 days. With change-point analysis, CAO was minimal beyond postoperative day 158., Conclusion: CAO can occur in up to 18% of patients and the first 5-month post-operative period is critical for surveillance. LO is associated with better outcomes compared to EO unless there is inadequate portal venous inflow., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
40. Novel technique in treating portal cavernous transformation with portal Biliopathy.
- Author
-
Zhang AD and Bergen M
- Subjects
- Humans, Portal Vein diagnostic imaging, Portal Vein surgery, Treatment Outcome, Portasystemic Shunt, Transjugular Intrahepatic methods
- Abstract
We present a case report of a patient who is a non-cirrhotic with portal cavernous transformation secondary to previous trauma. The patient presents with portal biliopathy requiring ERCP/EUS with biliary stenting. The patient was referred to Interventional Radiology (IR) for portal vein recanalization. The patient underwent a novel technique of transplenic access with portal vein recanalization via a gunsight technique, ultimately receiving a direct intrahepatic portocaval shunt (DIPS). Subsequently, his symptoms resolved, and the biliary stent was successfully removed., Competing Interests: Declarations of Interest None., (Copyright © 2022 National Medical Association. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
41. The "Hand as Foot" teaching method in the branching of the intrahepatic portal vein.
- Author
-
Jia P, Deng L, Yan L, and Liu D
- Subjects
- Abdomen, Humans, Liver blood supply, Portal Vein surgery
- Published
- 2022
- Full Text
- View/download PDF
42. Outcome of living donor liver transplantation in patients with preoperative portal vein thrombosis.
- Author
-
Kamal H, El Gendy E, Abdelkader NA, Bahaa M, Montasser IF, and Badran EM
- Subjects
- Child, Humans, Living Donors, Portal Vein surgery, Prospective Studies, Retrospective Studies, Severity of Illness Index, Treatment Outcome, End Stage Liver Disease etiology, Liver Diseases complications, Liver Transplantation adverse effects, Venous Thrombosis complications, Venous Thrombosis surgery
- Abstract
Background and Study Aims: Portal vein thrombosis (PVT) is no longer an absolute contraindication for living donor liver transplantation (LDLT). This study aimed to assess the short-term outcomes of LDLT and compare the 1-year survival rates between patients with and without preoperative PVT., Patients and Methods: This combined prospective and retrospective cohort study was conducted on patients who underwent LDLT at Ain Shams Centre for Organ Transplantation (ASCOT) between 2008 and 2020. The study included 60 patients with PVT and 60 patients without PVT. The two groups were compared in terms of preoperative data, operative details, postoperative complications, and 1-year survival., Results: Most patients with PVT were Child C (65%) and had higher model for end stage liver disease scores (16.23 ± 4.03) compared to the non-PVT group (13.9 ± 4.5). The PVT group showed longer cold ischemic time (CIT), hospital stay, and intensive care unit stay and significantly shorter 1-year survival rate (63.3%) compared to the non-PVT group (86.7%) (P = 0.003). Those with PVT grades I, II, and III had 1-year survival rates of 72.5%, 50%, and 40%, respectively., Conclusion: Preoperative PVT reduces the 1-year survival after transplantation, with patients with higher PVT grades exhibiting lower 1-year survival. LDLT for PVT still remains challenging and requires further studies., Competing Interests: Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
43. Branching patterns of the left portal vein and consequent implications in liver surgery: The left anterior sector.
- Author
-
Garancini M, Scotti MA, Gianotti L, Rovere A, Uggeri F, Braga M, and Romano F
- Subjects
- Hepatic Veins, Humans, Liver blood supply, Liver surgery, Portal Vein surgery
- Published
- 2022
- Full Text
- View/download PDF
44. Magnetic-assisted laparoscopic liver transplantation in swine.
- Author
-
Feng Z, Wang SP, Wang HH, Lu Q, Qiao W, Wang KL, Ding HF, Wang Y, Wang RF, Shi AH, Ren BY, Jiang YN, He B, Yu JW, Wu RQ, and Lv Y
- Subjects
- Anastomosis, Surgical methods, Animals, Humans, Living Donors, Magnetic Phenomena, Portal Vein diagnostic imaging, Portal Vein surgery, Swine, Vena Cava, Inferior surgery, Laparoscopy, Liver Transplantation methods
- Abstract
Background: Although laparoscopic technology has achieved rapid development in the surgical field, it has not been applied to liver transplantation, primarily because of difficulties associated with laparoscopic vascular anastomosis. In this study, we introduced a new magnetic-assisted vascular anastomosis technique and explored its application in laparoscopic liver transplantation in pigs., Methods: Two sets of magnetic vascular anastomosis rings (MVARs) with different diameters were developed. One set was used for anastomosis of the suprahepatic vena cava (SHVC) and the other set was used for anastomosis of the infrahepatic vena cava (IHVC) and portal vein (PV). Six laparoscopic orthotopic liver transplantations were performed in pigs. Donor liver was obtained via open surgery. Hepatectomy was performed in the recipients through laparoscopic surgery. Anastomosis of the SHVC was performed using hand-assisted magnetic anastomosis, and the anastomosis of the IHVC and PV was performed by magnetic anastomosis with or without hand assistance., Results: Liver transplants were successfully performed in five of the six cases. Postoperative ultrasonographic examination showed that the portal inflow was smooth. However, PV bending and blood flow obstruction occurred in one case because the MVARs were attached to each other. The durations of loading of MVAR in the laparoscope group and manual assistance group for IHVC and PV were 13 ± 5 vs. 5 ± 1 min (P < 0.01) and 10 ± 2 vs. 4 ± 1 min (P < 0.05), respectively. The durations of MVAR anastomosis in the laparoscope group and manual assistance group for IHVC and PV were 5 ± 1 vs. 1 ± 1 min (P < 0.01), and 5 ± 1 vs. 1 ± 1 min (P < 0.01), respectively. The anhepatic phase was 43 ± 4 min in the laparoscope group and 23 ± 2 min in the manual assistance group (P < 0.01)., Conclusions: Our study showed that magnetic-assisted laparoscopic liver transplantation can be successfully carried out in pigs., Competing Interests: Competing interest No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article., (Copyright © 2022 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
45. softALPPS - A novel, individual procedure for patients with advanced liver tumors.
- Author
-
Steffani M, Stöss C, Laschinger M, Assfalg V, Schulze S, Mogler C, Lohöfer F, Paprottka P, Hüser N, Friess H, Hartmann D, and Novotny A
- Subjects
- Hepatectomy, Humans, Ligation methods, Liver pathology, Portal Vein pathology, Portal Vein surgery, Treatment Outcome, Carcinoma, Hepatocellular surgery, Liver Neoplasms
- Abstract
Background: The first-line therapy for liver malignancies is a radical extended liver resection. This high-risk operation has a high incidence of post-hepatectomy liver failure (PHLF) due to a small future liver remnant (FLR). One of the procedures to increase the FLR is the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) which is still associated with high morbidity and mortality. Here, we present a new, less invasive ALPPS variant that may be associated with lower morbidity., Methods: SoftALPPS is characterized by reduced trauma to the liver tissue and individual adaptation to the patient's health constitution. In softALPPS, portal vein embolization (PVE) is performed instead of portal vein ligation (PVL) after complete recovery of liver function. In addition, a non-absorbable foil was avoided in order to be able to extend the interval to step two or skip step two when required., Results: Four patients successfully underwent softALPPS. Two of these patients have been followed-up for over a year (one patient with Klatskin tumor, one patient with extensive HCC). Both patients show no evidence of recurrence after 12 months and are in good medical condition. The other two patients who recently had surgery are also doing well., Conclusion: SoftALPPS offers the chance to curatively resect patients with high tumor burden of the liver even when the FLR is inadequate. This individual therapy method can give patients the possibility of complete tumor resection and can help to reduce perioperative morbidity., (Copyright © 2022 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
46. Patency for autologous vein is superior to cadaveric vein in portal-mesenteric venous reconstruction.
- Author
-
Sutton TL, Sandoval V, Warner D, Moneta G, Gilbert E, Mayo SC, Politano AD, Maynard E, Sheppard BC, and Enestvedt CK
- Subjects
- Cadaver, Humans, Portal Vein pathology, Portal Vein surgery, Retrospective Studies, Treatment Outcome, Vascular Patency, Pancreatic Neoplasms pathology
- Abstract
Background: Portal venous reconstruction (PVR) is often needed during resection of hepatopancreato-biliary (HPB) malignancies. Primary repair (PR), autologous vein (AV), or cryopreserved cadaveric vein (CCV) are frequently utilized, however relative patency is not well studied., Methods: All patients undergoing PVR between 2007-2019 at our center were identified. 3-year primary patency (PP), overall survival (OS), and survival-adjusted patency (SAP) were evaluated with Kaplan-Meier and Cox proportional hazards modeling., Results: One-hundred-twenty patients were identified with a median follow-up of 11 months. PR, AV, and CCV reconstruction were used in 28 (23%), 35 (29%), and 57 (48%) patients, respectively, with two (7%), four (11%), and 29 (51%) thromboses, respectively. 3-year PP was greater for both primary repair (90%) and AV (83%) compared to CCV (33%, both p<0.001). On multivariable analysis, CCV had worse 3-year PP (HR 7.89, p=0.005) and SAP (HR 2.09, p=0.02) compared to PR; AV reconstruction had equivalent oncologic and patency-related outcomes to PR (p>0.4 for both comparisons)., Conclusions: Primary patency for PR and AV reconstruction is superior to CCV for PVR during resection of HPB malignancies. AV conduit should be the preferred choice of reconstruction when PR is not achievable. Surgeons should only use CCV when factors preclude PR/AV reconstruction., (Copyright © 2022 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
47. Portal vein thrombosis after right hepatectomy: impact of portal vein resection and morphological changes of the portal vein.
- Author
-
Terasaki F, Ohgi K, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Yamada M, Otsuka S, Aramaki T, and Uesaka K
- Subjects
- Hepatectomy adverse effects, Hepatectomy methods, Humans, Liver Cirrhosis surgery, Portal Vein diagnostic imaging, Portal Vein pathology, Portal Vein surgery, Retrospective Studies, Splenectomy adverse effects, Liver Diseases surgery, Venous Thrombosis diagnostic imaging, Venous Thrombosis etiology, Venous Thrombosis pathology
- Abstract
Background: Right hepatectomy occasionally requires portal vein resection (PVR) and causes postoperative portal vein thrombosis (PVT)., Methods: A total of 247 patients who underwent right hepatectomy were evaluated using a three-dimensional analyzer to identify the morphologic changes in the portal vein (PV). The patients' characteristics were compared between the PVR group (n = 73) and non-PVR group (n = 174), and risk factors for PVT were investigated. The PVR group were subdivided into the wedge resection (WR) group (n = 38) and segmental resection (SR) group (n= 35)., Results: Postoperative PVT occurred in 20 patients (8.1%). Multivariate analyses in all patients revealed that postoperative left PV diameter/main PV diameter (L/M ratio) <0.56 (odds ratio [OR] 4.00, p = 0.009) and PVR (OR 3.31, p = 0.031) were significant risk factors for PVT. In 73 patients who underwent PVR, PVT occurred in 14 (19%) and WR (OR 11.5, p = 0.005) and L/M ratio <0.56 (OR 5.51, p = 0.016) were significant risk factors for PVT., Conclusion: PVR was one of the significant risk factors for PVT after right hepatectomy. SR rather than WR may be recommended for preventing PVT., Competing Interests: Conflict of interest None to declare., (Copyright © 2021 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
48. Response to pretransplant downstaging therapy predicts patient outcome after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus.
- Author
-
Yang Z, Sun JQ, Wang S, Zhuang L, and Zheng SS
- Subjects
- Humans, Portal Vein diagnostic imaging, Portal Vein pathology, Portal Vein surgery, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, Liver Neoplasms pathology, Liver Neoplasms surgery, Liver Transplantation, Thrombosis
- Published
- 2022
- Full Text
- View/download PDF
49. Combination of renoportal anastomosis and inferior mesenteric vein-portal anastomosis in liver transplantation: A new portal reconstruction technique.
- Author
-
Lin GL, Xiao M, Zhuang L, Yang Y, Li QY, Lu JF, Li MX, and Zheng SS
- Subjects
- Anastomosis, Surgical methods, Humans, Mesenteric Veins diagnostic imaging, Mesenteric Veins surgery, Portal Vein diagnostic imaging, Portal Vein surgery, Vascular Surgical Procedures methods, Liver Transplantation methods
- Published
- 2022
- Full Text
- View/download PDF
50. Minimizing the risk of small-for-size syndrome after liver surgery.
- Author
-
Papamichail M, Pizanias M, and Heaton ND
- Subjects
- Hepatectomy methods, Humans, Liver pathology, Liver surgery, Liver Regeneration, Portal Vein surgery, Treatment Outcome, Liver Failure surgery, Liver Neoplasms pathology
- Abstract
Background: Primary and secondary liver tumors are not always amenable to resection due to location and size. Inadequate future liver remnant (FLR) may prevent patients from having a curative resection or may result in increased postoperative morbidity and mortality from complications related to small-for-size syndrome (SFSS)., Data Sources: This comprehensive review analyzed the principles, mechanism and risk factors associated with SFSS and presented current available options in the evaluation of FLR when planning liver surgery. In addition, it provided a detailed description of specific modalities that can be used before, during or after surgery, in order to optimize the conditions for a safe resection and minimize the risk of SFSS., Results: Several methods which aim to reduce tumor burden, preserve healthy liver parenchyma, induce hypertrophy of FLR or prevent postoperative complications help minimize the risk of SFSS., Conclusions: With those techniques the indications of radical treatment for patients with liver tumors have significantly expanded. The successful outcome depends on appropriate patient selection, the individualization and modification of interventions and the right timing of surgery., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.